Creative BioMart is a well-known expert who is committed to developing a variety of protein therapies to improve the effectiveness and safety of protein therapy, and to allow the production of new types of proteins and effects. With years of experience, we provide customized services for major TCR-like antibodies as protein therapeutics to precisely meet customer requirements.

Introduction of Therapeutic TCR-Like Antibodies

Cancer immunotherapy centered on antibody therapy has achieved remarkable success in recent years, but traditional antibodies are still difficult to target intracellular antigens. TCR-like antibodies, which are being developed as a new class of immunotherapies, can recognize peptide/MHC complexes on the surface of tumor cells. TCR-like antibodies perform specific and pronounced antitumor immunity through several distinct molecular mechanisms, playing an important role in immunotherapy in melanoma, leukemia, breast, colon, and prostate tumor models. In addition to their therapeutic capabilities, TCR-like antibodies have been developed as diagnostic reagents for cancer and infectious diseases, and as valuable research tools to study MHC classⅠ antigen presentation.

Fig 1. Mechanism of action of TCR-like antibodies against cancer cells. (Yang X, et al., 2019)

Services

TCR-like antibodies combine the recognition of intracellular proteins with the therapeutic potency and versatility of monoclonal antibodies (mAbs), providing an unparalleled opportunity to expand the repertoire of therapeutic antibodies that can be used to treat diseases such as cancer. As a leading service provider of protein engineering, Creative BioMart has established a powerful TCR-like antibody platform to develop TCR-like antibodies and produce MHC/peptide complexes for TCR-like antibody discovery. In addition, we offer different methods (SPR, BLI and ITC) for affinity characterization to verify the quality of TCR-like antibodies.

The development of antibodies against disease-associated MHC-peptide complexes has led to the introduction of TCR-like antibodies. Our scientists have developed strategies to generate TCR-like antibodies against growing cancers, including but not limited to:

• Bivalent IgG isotype antibodies produced by hybridoma technology: immunogen preparation is one of the major limitations of TCR-like antibody discovery. We use traditional hybridoma technology to present recombinant MHC peptide complexes with strong immunogenic peptides as immunogens, which are suitable for the isolation of TCR-like antibodies that bind to MHC-peptide complexes with high affinity.
• scFv or Fab fragments produced by phage display: phage-based methods are used to isolate recombinant antibodies with the desired specificity, providing a new means for the production of TCR-like antibodies. The advantage of this technique is the high selectivity for the desired antigen.

Applications of Therapeutic TCR-Like Antibodies

TCR-like antibodies are redefining the selection of suitable targets in cancer therapy and may open the door to new areas of antibody therapy. With the deepening of exploration, TCR-like antibodies have a wide variety of applications, including:

• TCR-like antibodies can be used to directly observe the presence of MHC peptide complexes by standard methods such as flow cytometry.
• TCR-like antibodies can be used to analyze immunotherapy-based approaches, and TCR-like antibodies can provide new data on antigen presentation in various cells.
• TCR-like antibodies provide new powerful means to study structure-function relationships in the context of MHC peptides.
• TCR-like antibodies can be used as targeting moieties in various antibody-based immunotherapy approaches, with high specificity for very precise and unique human tumor antigens.

Creative BioMart is committed to providing TCR-like antibody services to global pharmaceutical companies, from immunogen production to antibody characterization, to accelerate the development of therapeutic antibody drugs. We will work with you to develop the most appropriate strategy and provide the most meaningful data for your research for accelerating the research of life sciences. If you are interested in our services, please do not hesitate to contact us for more information.

References

1. He Q, Liu Z, Liu Z, et al.. (2019) TCR-like antibodies in cancer immunotherapy. Journal of hematology & oncology. 12(1): 1-13.
2. Yang X, Xie S, Yang X, et al.. (2019) Opportunities and challenges for antibodies against intracellular antigens. Theranostics. 9(25): 7792.

• Engineering of Therapeutic Antibodies
• Engineering of Therapeutic Coagulation Factors
• Engineering of Therapeutic Cytokines and Receptors
• Engineering of Therapeutic Enzyme
• Engineering of Therapeutic Major Histocompatibility Complex Proteins
• Engineering of Therapeutic Protein Hormones
• Engineering of Therapeutic T Cell Receptors